Longitudinal Evaluation of the Distribution of Intraretinal Hyper-Reflective Foci in Eyes with Intermediate Age-Related Macular Degeneration

References

• Wang JJ, Foran S, Smith W, Mitchell P. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol. 2003;121(5):658–663. doi:10.1001/archopht.121.5.658.
   PubMedGoogle Scholar
• Ho J, Witkin AJ, Liu J, Chen Y, Fujimoto JG, Schuman JS, Duker JS. Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2011;118(4):687–693. doi:10.1016/j.ophtha.2010.08.010. Epub 2010 Nov 20.
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Heussen FM, Hariri A, Keane PA, Sadda SR. Optical coherence tomography-based observation of the natural history of drusenoid lesion in eyes with dry age-related macular degeneration. Ophthalmology. 2013;120(12):2656–2665. doi:10.1016/j.ophtha.2013.05.029. Epub 2013 Jul 4.
   PubMed Web of Science ®Google Scholar
• Christenbury JG, Folgar FA, O'Connell RV, Chiu SJ, Farsiu S, Toth CA, Age-related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study Group. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology. 2013;120(5):1038–1045. doi:10.1016/j.ophtha.2012.10.018.
   PubMed Web of Science ®Google Scholar
• Lei J, Balasubramanian S, Abdelfattah NS, Nittala MG, Sadda SR. Proposal of a simple optical coherence tomography-based scoring system for progression of age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255(8):1551–1558. doi:10.1007/s00417-017-3693-y.
   PubMed Web of Science ®Google Scholar
• Sleiman K, Veerappan M, Winter KP, McCall MN, Yiu G, Farsiu S, Chew EY, Clemons T, Toth CA, Age-Related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study Group. Optical coherence tomography predictors of risk for progression to non-neovascular atrophic age-related macular degeneration. Ophthalmology. 2017;124(12):1764–1777. doi:10.1016/j.ophtha.2017.06.032.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Waldstein SM, Klimscha S, Sadeghipour A, Hu X, Gerendas BS, Osborne A, Bogunovic H. Prediction of individual disease conversion in early AMD using artificial intelligence. Invest Ophthalmol Vis Sci. 2018;59(8):3199–3208. doi:10.1167/iovs.18-24106.
   PubMed Web of Science ®Google Scholar
• Nassisi M, Fan W, Shi Y, Lei J, Borrelli E, Ip M, Sadda SR. Quantity of intraretinal hyperreflective foci in patients with intermediate age-related macular degeneration correlates with 1-year progression. Invest Ophthalmol Vis Sci. 2018;59(8):3431–3439. doi:10.1167/iovs.18-24143.
   PubMed Web of Science ®Google Scholar
• Nassisi M, Lei J, Abdelfattah NS, Karamat A, Balasubramanian S, Fan W, Uji A, Marion KM, Baker K, Huang X, et al. OCT risk factors for development of late age-related macular degeneration in the fellow eyes of patients enrolled in the HARBOR study. Ophthalmology. 2019;126(12):1667–1674. doi:10.1016/j.ophtha.2019.05.016.
   PubMed Web of Science ®Google Scholar
• Nittala MG, Song YE, Sardell R, Adams LD, Pan S, Velaga SB, Horst V, Dana D, Caywood L, Laux R, et al. AMISH EYE STUDY: baseline spectral domain optical coherence tomography characteristics of age-related macular degeneration. Retina. 2019;39(8):1540–1550. doi:10.1097/IAE.0000000000002210.
   PubMed Web of Science ®Google Scholar
• Waldstein SM, Vogl WD, Bogunovic H, Sadeghipour A, Riedl S, Schmidt-Erfurth U. Characterization of drusen and hyperreflective foci as biomarkers for disease progression in age-related macular degeneration using artificial intelligence in optical coherence tomography. JAMA Ophthalmol. 2020;138(7):740–747. doi:10.1001/jamaophthalmol.2020.1376.
   PubMed Web of Science ®Google Scholar
• Cao D, Leong B, Messinger JD, Kar D, Ach T, Yannuzzi LA, Freund KB, Curcio CA. Hyperreflective foci, optical coherence tomography progression indicators in age-related macular degeneration, include transdifferentiated retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2021;62(10):34. doi:10.1167/iovs.62.10.34.
   PubMed Web of Science ®Google Scholar
• Nittala MG, Corvi F, Maram J, Velaga SB, Haines J, Pericak-Vance MA, Stambolian D, Sadda SR. Risk factors for progression of age-related macular degeneration: population-based amish eye study. J Clin Med. 2022;11(17):5110. doi:10.3390/jcm11175110.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang C, Yang Q, Xie H, Zhang J, Qiu Q, Liu K, Luo D, Liu F, Zhang J. Imaging hyperreflective foci as an inflammatory biomarker after anti-VEGF Treatment in neovascular age-related macular degeneration patients with optical coherence tomography angiography. Biomed Res Int. 2021;2021:6648191. doi:10.1155/2021/6648191.
   PubMed Web of Science ®Google Scholar
• Pang CE, Messinger JD, Zanzottera EC, Freund KB, Curcio CA. The onion sign in neovascular age-related macular degeneration represents cholesterol crystals. Ophthalmology. 2015;122(11):2316–2326. doi:10.1016/j.ophtha.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Li M, Dolz-Marco R, Messinger JD, Wang L, Feist RM, Girkin CA, Gattoussi S, Ferrara D, Curcio CA, Freund KB. Clinicopathologic correlation of anti-vascular endothelial growth factor-treated type 3 neovascularization in age-related macular degeneration. Ophthalmology. 2018;125(2):276–287. doi:10.1016/j.ophtha.2017.08.019.
   PubMed Web of Science ®Google Scholar
• Balaratnasingam C, Messinger JD, Sloan KR, Yannuzzi LA, Freund KB, Curcio CA. Histologic and optical coherence tomographic correlates in drusenoid pigment epithelium detachment in age-related macular degeneration. Ophthalmology. 2017;124(5):644–656. doi:10.1016/j.ophtha.2016.12.034.
   PubMed Web of Science ®Google Scholar
• Zanzottera EC, Messinger JD, Ach T, Smith RT, Freund KB, Curcio CA. The project MACULA retinal pigment epithelium grading system for histology and optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56(5):3253–3268. doi:10.1167/iovs.15-16431.
   PubMed Web of Science ®Google Scholar
• Zanzottera EC, Messinger JD, Ach T, Smith RT, Curcio CA. Subducted and melanotic cells in advanced age-related macular degeneration are derived from retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2015;56(5):3269–3278. doi:10.1167/iovs.15-16432.
   PubMed Web of Science ®Google Scholar
• Verma A, Corradetti G, He Y, Nittala MG, Nassisi M, Velaga SB, Haines JL, Pericak-Vance MA, Stambolian D, Sadda SR. Relationship between the distribution of intra-retinal hyper-reflective foci and the progression of intermediate age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;261(12):3437–3447. doi:10.1007/s00417-023-06180-4. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Ferris FL, 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR, Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120(4):844–851. doi:10.1016/j.ophtha.2012.10.036.
   PubMed Web of Science ®Google Scholar
• Borrelli E, Abdelfattah NS, Uji A, Nittala MG, Boyer DS, Sadda SR. Postreceptor neuronal loss in intermediate age-related macular degeneration. Am J Ophthalmol. 2017;181:1–11. doi:10.1016/j.ajo.2017.06.005.
   PubMed Web of Science ®Google Scholar
• Tiosano L, Byon I, Alagorie AR, Ji YS, Sadda SR. Choriocapillaris flow deficit associated with intraretinal hyperreflective foci in intermediate age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2020;258(11):2353–2362. doi:10.1007/s00417-020-04837-y.
   PubMed Web of Science ®Google Scholar
• Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T. Retinal microglia: just bystander or target for therapy? Prog Retin Eye Res. 2015;45:30–57. doi:10.1016/j.preteyeres.2014.11.004.
   PubMed Web of Science ®Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–675. doi:10.1038/nmeth.2089.
   PubMed Web of Science ®Google Scholar
• Sun Y, Gao L, Hou W, Wu J. β-sitosterol alleviates inflammatory response via inhibiting the activation of ERK/p38 and NF-κB pathways in LPS-exposed BV2 cells. Biomed Res Int. 2020;2020:7532306. doi:10.1155/2020/7532306.
   PubMed Web of Science ®Google Scholar
• Okunuki Y, Mukai R, Nakao T, Tabor SJ, Butovsky O, Dana R, Ksander BR, Connor KM. Retinal microglia initiate neuroinflammation in ocular autoimmunity. Proc Natl Acad Sci U S A. 2019;116(20):9989–9998. doi:10.1073/pnas.1820387116.
   PubMed Web of Science ®Google Scholar
• Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127(2):186–195. doi:10.1016/j.ophtha.2019.07.011.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Rosenfeld PJ, Waheed NK, Singh RP, Ronca N, Slakter JS, Staurenghi G, Monés J, Baumal CR, Saroj N, et al. Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy. Ophthalmology. 2021;128(9):1325–1336. doi:10.1016/j.ophtha.2021.02.025.
   PubMed Web of Science ®Google Scholar
• Steinle NC, Pearce I, Monés J, Metlapally R, Saroj N, Hamdani M, Ribeiro R, Rosenfeld PJ, Lad EM. Impact of baseline characteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetacoplan. Am J Ophthalmol. 2021;227:116–124. doi: 10.1016/j.ajo.2021.02.031.
   PubMed Web of Science ®Google Scholar
• Nittala MG, Metlapally R, Ip M, Chakravarthy U, Holz FG, Staurenghi G, Waheed N, Velaga SB, Lindenberg S, Karamat A, et al. Association of pegcetacoplan with progression of incomplete retinal pigment epithelium and outer retinal atrophy in age-related macular degeneration: a post hoc analysis of the FILLY randomized clinical trial. JAMA Ophthalmol. 2022;140(3):243–249. doi:10.1001/jamaophthalmol.2021.6067.
   PubMed Web of Science ®Google Scholar